Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey

American Journal of Hematology

Volumn 91, Issue 11, 2016, Pages 1076-1081

  Trecarichi, Enrico Maria ^a   Pagano, Livio ^a   Martino, Bruno ^b   Candoni, Anna ^c   Di Blasi, Roberta ^a   Nadali, Gianpaolo ^d   Fianchi, Luana ^a   Delia, Mario ^e   Sica, Simona ^a   Perriello, Vincenzo ^f   Busca, Alessandro ^g   Aversa, Franco ^h   Fanci, Rosa ⁱ   Melillo, Lorella ^j   Lessi, Federica ^k   Del Principe, Maria Ilaria ^l   Cattaneo, Chiara ^m   Tumbarello, Mario ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

^g CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

^m Hematology Unit   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CARBAPENEM DERIVATIVE;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BLOODSTREAM INFECTION; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; ITALIAN (CITIZEN); KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MONOTHERAPY; MORTALITY RATE; NEUTROPHIL COUNT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; TERTIARY CARE CENTER; TREATMENT DURATION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; HEMATOLOGIC NEOPLASMS; ITALY; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER;

ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CARBAPENEMS; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; ITALY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84991806410     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24489     Document Type: Article

References (34)

1. Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: Current epidemiology and clinical impact. Curr Opin Infect Dis 2014;27:200–210.
2. Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey. Clin Microbiol Infect 2015;21:337–343.
3. Montassier E, Batard E, Gastinne T, et al. Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013;32:841–850.
4. Menzo SL, la Martire G, Ceccarelli G, et al. New insight on epidemiology and management of bacterial bloodstream infection in patients with hematological malignancies. Mediterr J Hematol Infect Dis 2015;7:e2015044.
5. Viale P, Giannella M, Lewis R, et al. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013;11:1053–1063.
6. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785–796.
7. Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis 2014;20:1235–1236.
8. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from Italy. Bone Marrow Transplant 2015;50:282–288.
9. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
10. European Centre for Disease Prevention and Control. Healthcare-associated infections. Available at http://ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf#page=27. [accessed 15.05.2016]
11. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98:1826–1835.
12. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.
13. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427–431.
14. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165–228.
15. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Available at http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf. [accessed 15.05.2016]
16. Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: Results from a multicenter case-control-control study. Clin Microbiol Infect 2015;21:1106.e1–8.
17. Tumbarello M, Trecarichi EM, Tumietto F, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014;58:3514–3520.
18. Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clin Microbiol Infect 2014;20:1357–1362.
19. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012;55:943–950.
20. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322–2328.
21. Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. Int J Antimicrob Agents 2016;47:335–339.
22. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133–2143.
23. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17:1798–1803.
24. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: Risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3244–3252.
25. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014;20:1170–1175.
26. Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 2009;64:320–326.
27. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009;58:299–307.
28. Paterson DL. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008;47:S14–S20.
29. Verroken A, Defourny L, le Polain de Waroux O, et al. Clinical impact of MALDI-TOF MS identification and rapid susceptibility testing on adequate antimicrobial treatment in sepsis with positive blood cultures. PLoS One 2016;11:e0156299.
30. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: Risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011;66:657–663.
31. Trecarichi EM, Tumbarello M, Caira M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 2011;96:e1–3.
32. Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: A retrospective cohort study. J Antimicrob Chemother 2015;70:3146–3153.
33. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014;58:1274–1283.
34. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69:2305–2309.